Document is current

Article History

Received: 21 January 2021

Accepted: 8 March 2023

First Online: 27 March 2023

Competing interests

: The authors declare no competing non-financial interests but the following competing financial interests: C.V.F. received a grant from Association Nationale de la Recherche et de la Technologie (A.N.R.T.) and full-time employment by Air Liquide Healthcare. F.M., Y.R., S.L. and S.H. declared full-time employment by Air Liquide Healthcare at the time of the study. J.C.C. served on advisory boards for Air Liquide, Biogen, BrainEver, Denali, EverPharma, Prevail Therapeutic, UCB, and received grants from Sanofi outside of this work. I.B. served on scientific advisory boards for AbbVie and Orkyn. D.B. received travel grants from Boston Scientific and research support grant from Fondation Recherche Médicale. M.B. reports reimbursement of travel expenses to scientific meetings from ELIVIE, Medtronic and Boston Scientific, honoraria from Merz Pharma and Allergan for lecturing, outside the submitted work. V.C.D.C. and S.F. declare no conflict of interest. S.D. declares boards and congress with Medtronic, Orkyn, AbbVie, LVL, Homeperf, Elivie. C.G. received grants from Abbot and Abbvie. D.D. served on several Scientific Advisory Boards for Orkyn, Air Liquide, Lundbeck, Ever Pharma and Boston Scientific, he has equity stake in InBrain Pharma. D.G. received grants from AP-HP (DRC-PHRC) and France Parkinson, served on scientific advisory boards for AbbVie and Zambon; received research funding from Air Liquide; received speech honorarium from Medtronic, Abbvie and Merz; received travel funding from Abbvie and Merz.